Skip to main content

Conference Correspondent

Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
The United States may be in the midst of an opioid epidemic, but the undertreatment of pain remains an issue for patients with cancer. Read Bio ›

Although transplantation offers cures or durable remissions for malignancies, relapse is a frequent occurrence in many diseases, and remains a major cause of mortality. Read Bio ›

Despite significant progress in stem-cell transplantations over the past decade, graft-versus-host disease (GVHD) remains the leading cause of nonrelapse death in this patient population. Read Bio ›


According to the re­sults of a recent survey of hematopoietic stem-cell transplantation (HSCT) professionals, burnout is prevalent across all HSCT disciplines, with pharmacists showing the highest rates of burnout and moral distress. Read Bio ›


Washington, DC—The combination of nivolumab plus ipilimumab improved survival compared with ipilimumab alone in patients with previously untreated advanced melanoma, according to updated results of the phase 3 CheckMate-067 clinical trial presented at the 2017 meeting of the American Association for Cancer Research. A descriptive analysis suggested that the combination was superior to nivolumab monotherapy, although that was not a prespecified end point of the study. Read Bio ›

As new drugs are introduced into the clinic, an active area of research is the identification of biomarkers for response that would inform oncologists about which patients are likely to respond. Read Bio ›

Abemaciclib, a cyclin-dependent kinase (CDK)4/6 inhibitor, achieved an objective response in 1 of 5 heavily pretreated patients with metastatic hormone receptor–positive/HER2-negative (HR+/HER2–) breast cancer. Read Bio ›

Somatostatin analogs have multiple roles in the treatment of neuroendocrine tumors (NETs), including the management of symptoms of hormone hypersecretion and, more recently, slowing tumor progression. Read Bio ›